Bukwang and Pharmasset announced at April 27, 2006 that a

presentation of the preliminary results of a Korean Phase III clinical

trial of Clevudine for the treatment of Hepatitis B will be made

during the 41st Annual Meeting of the European Association for

the Study of the Liver (EASL) being held in Vienna, Austria from

April 26-30, 2006. Dr. Young Hwa Chung of the Department of

Medicine at Asan Medical Center, Ulsan University in Seoul, South

Korea presented 48-week clinical data, entitled “One-year

treatment with Clevudine demonstrated significant viral

suppression and biochemical improvement,” on Friday, April 28,

2006 at 5:45pm (CEST) during EASL’s Parallel Session 5:

Hepatitis B Disease and Therapy.

Clevudine-Study303-EASL2006.pdf